查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1981505

子宮內膜癌治療市場：2026年至2032年全球市場預測（依治療方法、藥物類別、治療階段、給藥部位及給藥途徑分類）

Endometrial Cancer Treatment Market by Treatment Type, Drug Class, Line Of Therapy, Administration Setting, Mode Of Administration - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，子宮內膜癌治療市場價值將達到 93.8 億美元，到 2026 年將成長至 99.3 億美元，到 2032 年將達到 157.7 億美元，複合年成長率為 7.69%。

主要市場統計數據
基準年 2025 93.8億美元
預計年份：2026年 99.3億美元
預測年份：2032年 157.7億美元
複合年成長率 (%) 7.69%

簡要說明了臨床實踐、診斷和醫療保健服務的最新進展，這些進展正在改變當今子宮內膜癌的治療模式。

子宮內膜癌的治療正在經歷一場快速的變革時期，無論在臨床層面還是操作層面，這都得益於分子層面的深入研究、治療方法的進步以及醫療服務體系的變革。腫瘤譜分析和基於生物標記的治療選擇技術的進步重塑了診斷流程，使臨床醫生不再僅僅依賴組織學檢查，而是轉向精準醫療模式，從而指導全身治療方案的選擇。同時，免疫調節療法和標靶治療相結合的聯合治療為以往治療選擇有限的患者拓展了治療選擇。此外，微創手術技術和前哨淋巴結定位技術降低了手術全期併發症，並縮短了患者的復原時間。

對模式轉移創新、生物標記主導策略以及醫療保健去中心化進行分析概述，這些正在重新定義子宮內膜癌的治療途徑。

子宮內膜癌的治療現狀正經歷著一場變革，其驅動力包括精準腫瘤學、聯合免疫療法、不斷完善的手術標準以及醫療服務的去中心化。分子分層提高了錯配修復（MMR）狀態和特定標靶突變等生物標記的重要性，影響臨床試驗的設計，並擴大了標靶治療的適用人群。同時，針對PD-1抑制劑和CTLA-4（通常與抗血管生成藥物和標靶治療聯合使用）的治療策略的興起，預示著治療方案正朝著多藥聯合全身治療的方向發展，旨在使更多患者獲得持續的療效。

本報告冷靜地評估了 2025 年實施的關稅主導貿易措施將如何影響治療和診斷管道的供應鏈韌性、籌資策略和臨床連續性。

美國2025年實施的關稅措施為整個子宮內膜癌治療系統帶來了一系列複雜的挑戰和調整，影響了供應鏈、臨床運作和籌資策略。部分進口藥品原料、診斷試劑和醫療設備關稅的提高，導致一些醫療機構和供應商的直接採購成本增加。為應對這項挑戰，採購團隊加快了供應商多元化，探索了替代採購契約，並加強了與國內生產合作夥伴的協作，以降低關稅波動帶來的風險。同時，各機構也努力維持臨床試驗的連續性，避免臨床實驗藥物供應中斷。

深入分析治療方法、藥物類別、治療方案、給藥途徑和臨床環境等細節，為研發和商業化決策提供支援。

在子宮內膜癌治療整體，明確治療細分對於將臨床創新轉化為營運和商業優先事項至關重要。治療方法細分包括化療、聯合治療、荷爾蒙療法、免疫治療、放射線治療、手術和標靶治療，每種療法在研發、給藥和報銷方面都存在不同的考量。依藥物類別進行詳細分類，可以進一步擴展此觀點，區分抗血管新生療法、化療藥物、荷爾蒙療法、免疫療法和標靶治療。此外，還可以進行亞細分，含鉑類藥物和紫杉烷類藥物列為化療藥物的亞類，將Aromatase抑製劑和孕激素列為荷爾蒙療法的亞類，將CTLA-4抑製劑和PD-1抑製劑列為免疫治療的亞類，將mTOR抑製劑、PARP抑製劑和蛋白酪氨酸激酶抑製劑列為標靶治療的亞類。依治療線進行細分，可捕捉第一線、二線、三線、四線及後續臨床序列的背景，進而決定臨床實驗終點、對照組選擇及支付方解釋。

反映細微區域差異的見解解釋了法規結構、診斷基礎設施和報銷模式如何影響世界各地市場的治療機會。

區域趨勢對子宮內膜癌治療和診斷的獲取管道、監管重點和普及率有顯著影響。在美洲，監管機構和支付者優先考慮衛生技術評估（HTA）和真實世界數據（RWE），同時許多醫療系統正在投資分子診斷能力和門診輸液中心，以改善醫療服務可近性並減少住院次數。這些區域性優先事項促進了在診斷網路完善的地區快速推廣基於生物標記的治療方法，但也凸顯了在先進診斷服務獲取仍然不均衡的地區存在的差距。

企業層面的策略觀察強調，投資組合多元化、夥伴關係模式和診斷整合是該領域的關鍵競爭優勢。

製藥、生物技術、診斷和醫療設備公司的企業策略正朝著整合解決方案的方向發展，這些解決方案融合了新型療法、伴隨診斷和病患支援專案。主要企業致力於建立多元化的產品組合，力求在突破性免疫療法和標靶治療與成熟的治療方法（如荷爾蒙療法和細胞毒性療法）之間取得平衡；而規模小規模的專業公司則專注於獨特的作用機制和生物標記主導的適應症。夥伴關係和策略聯盟日益專注於共同開發聯合治療、共同設計臨床試驗以加速向監管機構提交證據，以及透過許可協議擴大地域覆蓋範圍。

為領導者提供切實可行的建議，以加強診斷、實現供應鏈多元化、最佳化臨床策略並協調支付方合作，從而確保醫療服務的可近性和影響力。

產業領導者應優先進行一系列合作，在管控營運和市場進入風險的同時，將臨床創新轉化為對病患持久的益處。首先，投資強大的分子診斷項目和夥伴關係，以確保在生物標記主導療法中準確篩選患者。這包括支援病理檢測基礎設施和報銷管道的建設，以避免診斷瓶頸。其次，制定臨床開發計劃，評估第一線及後續治療方案（包括治療順序和聯合治療） ，同時納入患者報告結局（PRO）和真實世界數據（REW）的收集，並加強其在支付方諮詢和指南制定中的地位。

為了透明地說明檢驗收集和三角驗證的過程，整合臨床文獻、註冊資訊、相關人員訪談和營運分析，以得出嚴謹的結論。

本分析所依據的研究結合了對監管指南、同行評審的臨床文獻和公共臨床實驗室註冊資料的系統性回顧，以及對臨床醫生、支付方、診斷領域領導者和商業領域高管的專家訪談。二手資料提供了關於治療機制、近期核准和指南變更以及外科治療和門診護理進展的背景資訊。一手研究透過與熟悉臨床實驗室設計、檢查室運作、醫院採購和支付方決策的相關人員進行定性對話，檢驗了策略假設，並將臨床趨勢與實際情況進行了比對。

最終結論是將臨床創新和營運要求相結合，為改善所有護理路徑中的患者預後提供一致的願景。

總之，子宮內膜癌的治療格局呈現出一種建設性的張力：一方面是快速的臨床創新，另一方面是將這些創新成果惠及病患所需的複雜運作流程。基於生物標記的患者篩選、免疫療法與標靶治療的聯合應用，以及手術和門診管理的改進，都在拓展治療的可能性，同時也要求制定側重於新型診斷方法、物流以及與保險公司合作的策略。同時，貿易政策的變化和區域基礎設施的差異等外部因素，也要求製藥公司、醫療服務提供者和保險公司做出務實的調整，以確保臨床檢測的可近性和連續性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 子宮內膜癌治療市場：依治療方法

  • 化療
  • 聯合治療
  • 荷爾蒙療法
  • 免疫療法
  • 放射線治療
  • 外科手術
  • 分子標靶治療

第9章 子宮內膜癌治療市場：依藥物類別分類

  • 抗血管新生療法
  • 化療藥物
    • 含鉑類藥物
    • 紫杉烷類藥物
  • 荷爾蒙療法
    • Aromatase抑制劑
    • 黃體素
  • 免疫療法
    • CTLA-4抑制劑
    • PD-1抑制劑
  • 標靶治療
    • mTOR抑制劑
    • PARP抑制劑
    • 蛋白酪氨酸激酶抑制劑

第10章 子宮內膜癌治療市場：依治療階段分類

  • 第 1 行
  • 從第四行開始
  • 第二行
  • 第三行

第11章 子宮內膜癌治療市場：依醫療機構分類

  • 門診治療
  • 住院病人
  • 門診醫院

第12章 子宮內膜癌治療市場：依給藥途徑分類

  • 靜脈注射
  • 口服

第13章 子宮內膜癌治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 子宮內膜癌治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 子宮內膜癌治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國子宮內膜癌治療市場

第17章：中國子宮內膜癌治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AstraZeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Context Therapeutics Inc.
  • CooperSurgical Inc.
  • Eisai Co., Ltd.
  • Elekta AB
  • F. Hoffmann-La Roche AG
  • General Electric Company
  • GlaxoSmithKline PLC
  • Hologic Inc.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Koninklijke Philips NV
  • LiNA Medical ApS
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Siemens Healthineers AG
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-521BAA36EC26

The Endometrial Cancer Treatment Market was valued at USD 9.38 billion in 2025 and is projected to grow to USD 9.93 billion in 2026, with a CAGR of 7.69%, reaching USD 15.77 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.38 billion
Estimated Year [2026] USD 9.93 billion
Forecast Year [2032] USD 15.77 billion
CAGR (%) 7.69%

A concise introduction that contextualizes recent clinical, diagnostic, and care delivery advancements reshaping endometrial cancer treatment paradigms today

Endometrial cancer care has experienced an accelerated period of clinical and operational change driven by molecular insights, therapeutic innovation, and shifts in care delivery. Advances in tumor profiling and biomarker-driven treatment selection have reframed diagnostic pathways, enabling clinicians to move beyond histology alone toward precision approaches that guide systemic therapy choices. At the same time, combination regimens that pair immune modulation with targeted agents have expanded therapeutic options for patients who previously had limited choices, while minimally invasive surgical techniques and sentinel node mapping have reduced perioperative morbidity and shortened recovery timelines.

Transitioning from discovery to adoption, stakeholders across clinical, regulatory, and payer communities are aligning around evidence frameworks that emphasize meaningful clinical benefit and real-world effectiveness. Consequently, health systems and providers are adapting workflows to integrate outpatient-friendly administration modes and patient-reported outcome monitoring. These changes demand coordinated shifts in clinical operations, diagnostics infrastructure, and commercial strategies to ensure that innovations translate into improved patient outcomes and sustainable care pathways.

An analytical overview of paradigm-shifting innovations, biomarker-driven strategies, and care decentralization that are redefining endometrial cancer treatment pathways

The landscape of endometrial cancer treatment is undergoing transformative shifts driven by precision oncology, immunotherapy combinations, evolving surgical standards, and the decentralization of care. Molecular stratification has elevated the role of biomarkers such as mismatch repair status and specific actionable mutations, which in turn has influenced clinical trial design and broadened the population eligible for targeted interventions. Concurrently, the rise of PD-1 inhibitors and CTLA-4-directed strategies, often combined with antiangiogenic or targeted agents, illustrates a shift toward multimodal systemic regimens that seek to convert durable responses in a greater proportion of patients.

In parallel, care delivery is moving toward more outpatient-friendly models supported by oral targeted therapies and improved supportive care that reduce hospital stays. Surgical practice continues to evolve with less invasive approaches and enhanced recovery protocols that preserve quality of life. These dynamics are reinforcing cross-disciplinary collaborations among medical oncology, gynecologic surgery, radiation oncology, and molecular pathology. As a result, stakeholders are increasingly focused on evidence generation around combinatorial approaches, sequencing strategies across first line and subsequent lines of therapy, and the value proposition of precision diagnostics to guide therapeutic selection.

A clear-eyed assessment of how tariff-driven trade measures in 2025 have reshaped supply chain resilience, procurement strategies, and clinical continuity across treatment and diagnostic channels

The implementation of United States tariffs in 2025 has introduced a complex set of headwinds and adaptive responses across the endometrial cancer treatment ecosystem, touching supply chains, clinical operations, and procurement strategies. Increased duties on specific imported pharmaceutical components, diagnostic reagents, and medical devices have elevated direct procurement costs for some institutions and suppliers. In turn, procurement teams have accelerated supplier diversification, sought alternative sourcing agreements, and engaged more deeply with domestic manufacturing partners to mitigate exposure to tariff volatility. These operational adjustments have unfolded alongside efforts to preserve continuity of clinical trials and avoid interruptions to investigational agent supply.

Moreover, the tariffs have intensified scrutiny over inventory management and contractual terms across distributor networks, prompting stakeholders to renegotiate long-term agreements and to consider hedging strategies for critical consumables. Regulatory interactions and customs clearance processes have required closer coordination between manufacturers and supply chain partners to reduce lead times. Importantly, clinicians and health system leaders have focused on maintaining patient access by prioritizing treatment pathways that leverage locally produced agents or oral formulations less vulnerable to cross-border logistics constraints. Collectively, these adaptations reflect the sector's pragmatic approach to preserving treatment continuity and clinical research momentum in the face of evolving trade policy.

Deep segmentation-focused insights that connect treatment types, drug classes, lines of therapy, administration modes, and care settings to inform development and commercialization choices

Segmentation clarity is critical to translating clinical innovation into operational and commercial priorities across endometrial cancer care. Treatment type segmentation encompasses chemotherapy, combination therapy, hormone therapy, immunotherapy, radiation therapy, surgery, and targeted therapy, each of which presents different development, administration, and reimbursement considerations. Drug class granularity extends this view by distinguishing antiangiogenic therapy, chemotherapeutic agents, hormonal therapy, immunotherapy, and targeted therapy, with further subcategorization that highlights platinum based agents and taxanes under chemotherapeutics, aromatase inhibitors and progestins under hormonal therapy, CTLA-4 inhibitors and PD-1 inhibitors under immunotherapy, and mTOR inhibitors, PARP inhibitors, and tyrosine kinase inhibitors under targeted therapy. Line of therapy segmentation captures the clinical sequencing context across first line, second line, third line, and fourth line and beyond, which dictates trial endpoints, comparator selection, and payer narratives.

Mode of administration, separated into intravenous and oral delivery, informs site-of-care planning, adherence strategies, and patient support services. Meanwhile, administration setting-ambulatory care, hospital inpatient, and hospital outpatient-shapes operational workflows, capital requirements, and the economics of care delivery. Integrating these segmentation lenses enables stakeholders to pinpoint evidence gaps, prioritize development portfolios for specific clinical contexts, and design commercial models that reflect how treatments are used across real-world practice settings.

Regionally nuanced intelligence that explains how regulatory frameworks, diagnostic infrastructure, and reimbursement models influence therapeutic access across global markets

Regional dynamics exert a strong influence on access pathways, regulatory priorities, and adoption rates for endometrial cancer therapeutics and diagnostics. In the Americas, regulatory authorities and payers emphasize health technology assessment and real-world evidence, while many systems invest in molecular diagnostic capacity and outpatient infusion centers to improve access and reduce hospitalization. These regional priorities have supported rapid uptake of biomarker-driven treatments in settings with established diagnostic networks, but they have also underscored disparities where access to advanced diagnostics remains uneven.

Across Europe, Middle East & Africa, variations in national reimbursement frameworks, diagnostic infrastructure, and clinical guideline harmonization drive differentiated adoption. Stakeholders in these markets have placed emphasis on cross-border clinical collaborations, centralized pathology review for trial enrollment, and capacity building for precision diagnostics. In the Asia-Pacific region, accelerated investment in domestic biopharmaceutical capabilities, public-private partnerships, and expanding clinical trial activity have supported faster localization of novel agents. However, differences in regulatory pathways, pricing policies, and reimbursement timelines require tailored market entry strategies and adaptive evidence-generation plans to secure sustainable access across distinct national environments.

Strategic company-level observations that highlight portfolio diversification, partnership models, and diagnostic integration as key competitive differentiators in the sector

Corporate strategies across pharmaceutical, biotechnology, diagnostic, and device companies are converging on integrated solutions that pair novel therapeutics with companion diagnostics and patient support programs. Leading organizations focus on building diversified portfolios that balance transformational immunotherapies and targeted agents with established modalities such as hormonal and cytotoxic therapies, while smaller specialized firms concentrate on niche mechanisms and biomarker-driven indications. Partnerships and strategic alliances increasingly center on co-development of combination regimens, jointly designed trials that accelerate regulatory evidence, and licensing agreements that extend geographic reach.

In addition, contract research organizations and diagnostic manufacturers have intensified collaboration with sponsors to streamline trial enrollment through centralized testing and harmonized biomarker panels. Commercial teams are also evolving their engagement models to emphasize value communication toward payers and integrated delivery networks, leveraging health economic modeling and real-world data to substantiate comparative benefit. Across the competitive landscape, agility in clinical development, capabilities in companion diagnostics, and a demonstrated ability to negotiate access agreements will continue to separate market leaders from followers.

Action-oriented recommendations that guide leaders to strengthen diagnostics, diversify supply chains, optimize clinical strategies, and align payer engagement to secure access and impact

Industry leaders should prioritize a coordinated set of actions to translate clinical innovation into durable patient impact while managing operational and market access risks. First, invest in robust molecular diagnostic programs and partnerships to ensure accurate patient selection for biomarker-driven therapies; this includes supporting pathology capacity building and reimbursement pathways to avoid diagnostic bottlenecks. Next, design clinical development plans that evaluate sequencing and combinations across first-line and later lines of therapy, while embedding patient-reported outcomes and real-world evidence collection to strengthen payer discussions and guideline positioning.

Operationally, diversify supply chains and cultivate regional manufacturing partnerships to reduce tariff and logistical exposure, and adopt inventory strategies that preserve trial continuity. Commercially, develop value communication strategies that stress clinical differentiation, health economic impact, and adherence support, particularly for oral therapies that shift care to ambulatory and outpatient settings. Finally, engage early with payers and regulatory authorities to co-create evidence frameworks that accelerate access decisions and to pursue adaptive reimbursement approaches tied to outcomes data. Implementing these steps will enhance organizational resilience and increase the probability that clinical advances yield meaningful benefits at scale.

A transparent description of the evidence gathering and triangulation process integrating clinical literature, registries, stakeholder interviews, and operational analysis to produce rigorous insights

The research underpinning this analysis combined a structured review of regulatory guidance, peer-reviewed clinical literature, public clinical trial registries, and expert interviews with clinicians, payers, diagnostics leaders, and commercial executives. Secondary sources provided context on therapeutic mechanisms, recent approvals and guideline changes, and advances in surgical and outpatient care. Primary research validated strategic hypotheses through qualitative dialogues with stakeholders experienced in trial design, laboratory operations, hospital procurement, and payer decision-making, enabling triangulation of clinical trends with operational realities.

Data synthesis employed a thematic approach to map clinical innovations against care delivery models and regional access constraints. Methodological rigor included cross-validation of clinical endpoints, therapy sequences, and diagnostic dependencies, as well as sensitivity to policy and tariff shifts that affect supply chains. Limitations of the methodology include reliance on available public clinical data and stakeholder perspectives at a particular point in time; consequently, the analysis emphasizes evidence-based insights and actionable implications rather than speculative projections.

A definitive conclusion that synthesizes clinical innovations and operational imperatives into a coherent outlook for delivering improved patient outcomes across care pathways

In conclusion, the treatment landscape for endometrial cancer is characterized by a productive tension between rapid clinical innovation and the operational complexities required to deliver those advances to patients. Biomarker-driven selection, immunotherapy and targeted agent combinations, and improvements in surgical and outpatient management are converging to broaden therapeutic possibilities and to demand new diagnostic, logistical, and payer-aligned strategies. At the same time, external factors such as trade policy shifts and regional infrastructure variability require pragmatic adaptations by manufacturers, providers, and payers to safeguard access and clinical trial continuity.

Looking forward, success will accrue to organizations that integrate robust diagnostic capabilities, pursue rational combination and sequencing trials, and align commercial models with evolving care settings. By balancing scientific ambition with operational resilience and payer collaboration, stakeholders can convert promising clinical innovations into measurable improvements in patient outcomes and system sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endometrial Cancer Treatment Market, by Treatment Type

  • 8.1. Chemotherapy
  • 8.2. Combination Therapy
  • 8.3. Hormone Therapy
  • 8.4. Immunotherapy
  • 8.5. Radiation Therapy
  • 8.6. Surgery
  • 8.7. Targeted Therapy

9. Endometrial Cancer Treatment Market, by Drug Class

  • 9.1. Antiangiogenic Therapy
  • 9.2. Chemotherapeutic Agents
    • 9.2.1. Platinum Based Agents
    • 9.2.2. Taxanes
  • 9.3. Hormonal Therapy
    • 9.3.1. Aromatase Inhibitors
    • 9.3.2. Progestins
  • 9.4. Immunotherapy
    • 9.4.1. CTLA-4 Inhibitors
    • 9.4.2. PD-1 Inhibitors
  • 9.5. Targeted Therapy
    • 9.5.1. MTOR Inhibitors
    • 9.5.2. PARP Inhibitors
    • 9.5.3. Tyrosine Kinase Inhibitors

10. Endometrial Cancer Treatment Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Fourth Line And Beyond
  • 10.3. Second Line
  • 10.4. Third Line

11. Endometrial Cancer Treatment Market, by Administration Setting

  • 11.1. Ambulatory Care
  • 11.2. Hospital Inpatient
  • 11.3. Hospital Outpatient

12. Endometrial Cancer Treatment Market, by Mode Of Administration

  • 12.1. Intravenous
  • 12.2. Oral

13. Endometrial Cancer Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Endometrial Cancer Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Endometrial Cancer Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Endometrial Cancer Treatment Market

17. China Endometrial Cancer Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AstraZeneca PLC
  • 18.7. Bayer AG
  • 18.8. Becton, Dickinson and Company
  • 18.9. Boston Scientific Corporation
  • 18.10. Bristol-Myers Squibb Company
  • 18.11. Celgene Corporation
  • 18.12. Context Therapeutics Inc.
  • 18.13. CooperSurgical Inc.
  • 18.14. Eisai Co., Ltd.
  • 18.15. Elekta AB
  • 18.16. F. Hoffmann-La Roche AG
  • 18.17. General Electric Company
  • 18.18. GlaxoSmithKline PLC
  • 18.19. Hologic Inc.
  • 18.20. Johnson & Johnson Services, Inc.
  • 18.21. Karyopharm Therapeutics Inc.
  • 18.22. Koninklijke Philips N.V.
  • 18.23. LiNA Medical ApS
  • 18.24. Merck & Co., Inc.
  • 18.25. Novartis AG
  • 18.26. Pfizer Inc.
  • 18.27. Sanofi S.A.
  • 18.28. Siemens Healthineers AG
  • 18.29. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 202. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 226. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 227. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 232. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 236. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 237. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 242. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)